ReviewFrontiers in pharmacology2026
Pharmacological mechanisms of quercetin in liver and intestinal diseases: a gut-liver axis perspective.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic and gastrointestinal disorders share interconnected pathogenic mechanisms, yet their clinical management remains challenging. This has prompted interest in therapeutic approaches targeting the gut-liver axis. Quercetin, a natural flavonoid, has been studied in this context. To assess its pharmacological effects, we searched PubMed, Web of Science, EMBASE, and the Cochrane Library for literature published since 2000 on quercetin in hepatic and intestinal diseases. This review focuses on the gut-liver axis as a framework for understanding the pharmacological effects of quercetin. Mechanistically, quercetin modulates gut-liver communication by reshaping the gut microbiota, promoting short-chain fatty acid production, and modulating bile acid metabolism. In preclinical models, it has been reported to modulate FXR/TGR5 signaling and preserve intestinal barrier integrity, thereby reducing endotoxin translocation and systemic inflammation. These effects are associated with downstream modulation of oxidative, inflammatory, and apoptotic pathways, including NF-κB, PI3K/Akt, and Nrf2. Furthermore, preclinical evidence indicates that quercetin attenuates liver injury, MASLD/MASH, fibrosis, and hepatocellular carcinoma, and exerts protective effects in models of ulcerative colitis and colorectal cancer. However, most of this evidence comes from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.